Arbutus Biopharma Corp. (ABUS) Trading Down 1.5%
Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) were down 1.5% during mid-day trading on Friday . The stock traded as low as $3.71 and last traded at $3.93, with a volume of 139,359 shares. The stock had previously closed at $3.99.
Several analysts have recently issued reports on ABUS shares. Chardan Capital started coverage on Arbutus Biopharma Corp. in a report on Monday, May 16th. They set a “sell” rating and a $3.25 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Arbutus Biopharma Corp. in a report on Friday, April 22nd. Zacks Investment Research cut Arbutus Biopharma Corp. from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Finally, Leerink Swann reaffirmed a “buy” rating and set a $12.00 price objective on shares of Arbutus Biopharma Corp. in a report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $10.96.
The stock’s market capitalization is $213.58 million. The stock has a 50-day moving average of $3.72 and a 200 day moving average of $3.95.
Arbutus Biopharma Corp. (NASDAQ:ABUS) last posted its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.20. On average, equities analysts anticipate that Arbutus Biopharma Corp. will post ($1.49) EPS for the current year.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.